ref_name,rx_name,iso_name,section,assay_name,potency_type,potency,cumulative_count,potency_upper_limit,potency_lower_limit,potency_unit,date_added
Fabricius21,BNT_naive_1,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_2,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_3,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_4,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_5,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_6,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_7,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_8,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_9,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_10,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_11,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_12,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_13,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_14,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_15,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_16,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_17,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_18,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_19,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_20,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_21,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_22,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_23,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_24,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_25,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_26,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_27,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_28,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_29,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_30,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_31,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_32,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_33,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_34,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_35,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_36,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_37,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_38,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_39,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_40,Wuhan-Hu-1,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_41,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_42,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_43,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_44,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_45,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_46,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,78,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_47,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_48,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_49,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_50,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,56,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_51,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,48,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_52,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,48,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_53,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,82,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_54,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,75,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_55,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,73,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_56,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_57,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_58,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,85,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_59,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_60,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_61,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_62,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_63,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_64,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_65,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,78,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_66,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_67,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_68,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_69,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_70,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,75,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_71,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_72,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_73,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_74,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_75,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_76,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_77,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_78,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_79,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,85,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_80,S:501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_81,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_82,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_83,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_84,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_85,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_86,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_87,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_88,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_89,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_90,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,48,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_91,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,34,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_92,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,38,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_93,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_94,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,38,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_95,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_96,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,83,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_97,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_98,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_99,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,85,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_100,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_101,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,65,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_102,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_103,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,62,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_104,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,71,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_105,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_106,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_107,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,74,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_108,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_109,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,83,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_110,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_111,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,82,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_112,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,71,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_113,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_114,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_115,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_116,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,50,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_117,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_118,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_119,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_120,S:417N+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,40,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_121,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_122,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_123,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_124,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_125,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,40,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_126,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,51,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_127,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_128,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,85,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_129,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_130,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,50,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_131,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,28,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_132,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,43,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_133,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,51,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_134,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,39,1,100,30,percent,2021-11-01
Fabricius21,BNT_naive_135,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,59,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_136,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,77,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_137,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_138,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_139,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,81,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_140,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_141,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_142,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_143,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_144,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_145,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,39,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_146,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_147,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_148,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_149,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_150,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_151,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_152,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_153,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,81,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_154,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,62,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_155,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,52,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_156,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_157,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_158,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,82,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_159,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,62,1,100,30,percent,2021-11-01
Fabricius21,BNT_infected_160,S:417T+484K+501Y,Figure 2D,sVNT (ACE2 blocking assay),NC,38,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_161,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_162,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_163,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_164,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_165,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_166,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_167,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_168,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_169,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_170,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_171,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_172,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_173,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_174,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_175,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_176,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_177,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_178,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_179,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_180,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_181,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_182,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_183,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,78,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_184,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_185,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_186,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_187,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,59,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_188,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,10,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_189,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_190,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_191,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,65,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_192,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,75,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_193,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_194,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,74,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_195,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,71,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_196,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_197,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,51,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_198,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,56,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_199,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_200,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_201,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,65,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_202,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_203,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,73,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_204,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_205,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_206,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_207,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_208,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_209,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_210,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_211,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_212,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_213,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_214,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_215,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_216,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_217,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_218,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_219,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,82,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_220,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_221,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_222,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_223,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_224,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_225,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_226,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,77,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_227,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_228,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_229,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,78,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_230,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_231,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,89,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_232,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_233,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_234,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_235,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,74,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_236,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_237,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_238,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_239,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_240,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,77,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_241,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_242,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_243,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_244,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_245,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_246,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_247,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_248,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_249,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_250,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_251,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_252,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_253,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_254,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_255,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_256,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_257,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_258,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,35,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_259,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_260,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,40,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_261,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,77,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_262,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,46,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_263,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_264,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_265,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_266,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_267,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_268,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_269,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_270,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,78,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_271,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_272,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,83,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_273,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_274,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_275,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_276,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_277,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_278,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_279,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_280,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_281,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_282,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_283,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_284,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_285,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_286,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_287,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_288,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_289,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_290,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_291,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_292,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_293,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_294,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_295,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,83,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_296,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_297,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_298,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_299,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_300,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_301,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,75,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_302,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_303,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,40,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_304,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,40,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_305,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,33,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_306,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,89,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_307,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_308,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_309,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_310,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_311,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,43,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_312,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_313,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,43,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_314,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,32,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_315,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,41,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_316,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,22,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_317,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_318,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,56,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_319,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_320,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_321,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_322,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,35,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_323,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,52,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_324,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,40,1,100,30,percent,2021-11-01
Fabricius21,CP_325,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,98,1,100,30,percent,2021-11-01
Fabricius21,CP_326,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_327,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,CP_328,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,CP_329,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_330,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_331,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,CP_332,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,CP_333,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,CP_334,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_335,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_336,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,CP_337,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,CP_338,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,CP_339,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,CP_340,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,CP_341,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,CP_342,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,CP_343,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,CP_344,Wuhan-Hu-1,Figure 5B,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_345,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,99,1,100,30,percent,2021-11-01
Fabricius21,CP_346,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,CP_347,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,CP_348,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,CP_349,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,CP_350,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,CP_351,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,CP_352,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,CP_353,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,CP_354,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,CP_355,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,CP_356,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,CP_357,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,CP_358,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,CP_359,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,122,1,100,30,percent,2021-11-01
Fabricius21,CP_360,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,CP_361,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,47,1,100,30,percent,2021-11-01
Fabricius21,CP_362,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,43,1,100,30,percent,2021-11-01
Fabricius21,CP_363,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,56,1,100,30,percent,2021-11-01
Fabricius21,CP_364,S:501Y,Figure 5B,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_365,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_366,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,65,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_367,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_368,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_369,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_370,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,99,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_371,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_372,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_373,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_374,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_375,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_376,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_377,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_378,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,62,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_379,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,34,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_380,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,46,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_381,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_382,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,51,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_383,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_384,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_385,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_386,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_387,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_388,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,38,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_389,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_390,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_391,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,77,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_392,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_393,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,82,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_394,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,80,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_395,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_396,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,81,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_397,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_398,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_399,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_400,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,52,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_401,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,46,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_402,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_403,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_404,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_405,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_406,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,81,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_407,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_408,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,96,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_409,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,52,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_410,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_411,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_412,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_413,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,59,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_414,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_415,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_416,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,56,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_417,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,81,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_418,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,79,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_419,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_420,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_421,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,119,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_422,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_423,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_424,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,93,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_425,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_426,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_427,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,78,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_428,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_429,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,83,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_430,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_431,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,88,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_432,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,89,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_433,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_434,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,70,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_435,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_436,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,26,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_437,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,36,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_438,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,21,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_439,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_440,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_441,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,65,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_442,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,59,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_443,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,59,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_444,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_445,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_446,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,63,1,100,30,percent,2021-11-01
Fabricius21,CP_447,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_448,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,73,1,100,30,percent,2021-11-01
Fabricius21,CP_449,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,56,1,100,30,percent,2021-11-01
Fabricius21,CP_450,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,CP_451,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,64,1,100,30,percent,2021-11-01
Fabricius21,CP_452,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,47,1,100,30,percent,2021-11-01
Fabricius21,CP_453,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,37,1,100,30,percent,2021-11-01
Fabricius21,CP_454,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,89,1,100,30,percent,2021-11-01
Fabricius21,CP_455,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,151,1,100,30,percent,2021-11-01
Fabricius21,CP_456,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,95,1,100,30,percent,2021-11-01
Fabricius21,CP_457,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,54,1,100,30,percent,2021-11-01
Fabricius21,CP_458,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,67,1,100,30,percent,2021-11-01
Fabricius21,CP_459,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,92,1,100,30,percent,2021-11-01
Fabricius21,CP_460,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,50,1,100,30,percent,2021-11-01
Fabricius21,CP_461,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,149,1,100,30,percent,2021-11-01
Fabricius21,CP_462,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,CP_463,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,71,1,100,30,percent,2021-11-01
Fabricius21,CP_464,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,CP_465,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,46,1,100,30,percent,2021-11-01
Fabricius21,CP_466,S:417N+484K+501Y,Figure 5C,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_467,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,62,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_468,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_469,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,36,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_470,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,49,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_471,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,39,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_472,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,41,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_473,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,61,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_474,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_475,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,49,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_476,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,62,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_477,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,37,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_478,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,59,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_479,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_480,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,65,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_481,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,58,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_482,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,27,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_483,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,38,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_484,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,46,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_485,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,39,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_486,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_487,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,55,1,100,30,percent,2021-11-01
Fabricius21,BNT_2dose_488,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,49,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_489,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_490,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,19,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_491,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,52,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_492,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_493,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_494,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,50,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_495,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,74,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_496,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,69,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_497,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,39,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_498,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,72,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_499,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,53,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_500,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_501,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,82,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_502,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,25,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_503,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,10,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_504,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,73,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_505,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,49,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_506,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,43,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_BNT_507,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_508,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,73,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_509,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,34,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_510,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_511,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,13,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_512,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,60,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_513,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,28,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_514,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_515,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,42,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_516,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,36,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_517,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_518,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,42,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_519,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,75,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_520,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,68,1,100,30,percent,2021-11-01
Fabricius21,mRNA_2dose_521,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_522,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,91,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_523,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,45,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_524,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,83,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_525,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,76,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_526,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,90,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_527,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,84,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_528,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,31,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_529,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,66,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_530,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,36,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_531,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,74,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_532,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_533,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,77,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_534,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,87,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_535,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,86,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_536,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,57,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_mRNA_537,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,49,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_538,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,10,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_539,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,1,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_540,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,4,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_541,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,19,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_542,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,29,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_543,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,41,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_544,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,30,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_545,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,7,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_546,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,1,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_547,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,14,1,100,30,percent,2021-11-01
Fabricius21,AZD1222_2dose_548,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,1,1,100,30,percent,2021-11-01
Fabricius21,CP_549,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,97,1,100,30,percent,2021-11-01
Fabricius21,CP_550,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,30,1,100,30,percent,2021-11-01
Fabricius21,CP_551,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,19,1,100,30,percent,2021-11-01
Fabricius21,CP_552,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,20,1,100,30,percent,2021-11-01
Fabricius21,CP_553,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,32,1,100,30,percent,2021-11-01
Fabricius21,CP_554,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,25,1,100,30,percent,2021-11-01
Fabricius21,CP_555,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,22,1,100,30,percent,2021-11-01
Fabricius21,CP_556,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,50,1,100,30,percent,2021-11-01
Fabricius21,CP_557,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,13,1,100,30,percent,2021-11-01
Fabricius21,CP_558,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,34,1,100,30,percent,2021-11-01
Fabricius21,CP_559,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,25,1,100,30,percent,2021-11-01
Fabricius21,CP_560,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,37,1,100,30,percent,2021-11-01
Fabricius21,CP_561,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,33,1,100,30,percent,2021-11-01
Fabricius21,CP_562,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,25,1,100,30,percent,2021-11-01
Fabricius21,CP_563,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,94,1,100,30,percent,2021-11-01
Fabricius21,CP_564,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,20,1,100,30,percent,2021-11-01
Fabricius21,CP_565,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,29,1,100,30,percent,2021-11-01
Fabricius21,CP_566,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,29,1,100,30,percent,2021-11-01
Fabricius21,CP_567,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,16,1,100,30,percent,2021-11-01
Fabricius21,CP_568,S:417N+484K+501Y,Figure 5D,sVNT (ACE2 blocking assay),NC,47,1,100,30,percent,2021-11-01
